Lilly's weekly insulin succeeds in late-stage studies

[May 16, 2024]  (Reuters) -Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.

Lilly said that efsitora was equally safe and effective among adults who have previously not been on insulin therapy.

In both the studies, efsitora showed non-inferior reduction in blood sugar levels in patients, compared to the most commonly used daily long-acting insulins globally.

One of the studies also evaluated the weekly, long-acting insulin in patients who are currently using and not using GLP-1 therapies, Lilly said.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)

Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023 after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. REUTERS/Mike Blake

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.